Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Oncology

IDEAYA Biosciences Eyes Busy 2026 as Darovasertib Advances Toward FDA Filing

IDEAYA Biosciences (NASDAQ:IDYA) Chief Executive Yujiro Hata said the precision oncology company is preparing for a busy 2026, led by regulatory and clinical milestones for darovasertib in metastatic uveal melanoma and multiple data readouts across its pipeline. Speaking at a Stifel-hosted event, H

MarketBeat

Menarini Group Announces New Data at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

FLORENCE, Italy and NEW YORK, May 25, 2026 /PRNewswire/ -- The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, announced that new data related to elacestrant and…

AAP

Could Launching Tumors Into Space Help Medicine Beat Cancer?

A new experiment is seeking to validate whether living cancer samples can be prepared, operated, monitored, and recovered under flight conditions without crew intervention in their standardized format for pharma-grade preclinical research.

International Business Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference

Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined several upcoming clinical and regulatory priorities across oncology, inflammation and HIV during a discussion with RBC Capital Markets senior biotech analyst Brian Abrahams. Berger said Gilead is focused on advancing Trodel

MarketBeat

Venus Remedies gets Saudi FDA approval for speciality oncology therapy

Venus Remedies Limited has secured its first global marketing authorization for its specialty oncology therapy, Plerixafor, from the Saudi Food and Drug Authority (SFDA). This hematopoietic stem cell mobilizer is crucial for patients undergoing stem cell transplantation for multiple myeloma and non-Hodgkin lymphoma.

The Economic Times

Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer

Bicara Therapeutics (NASDAQ:BCAX) said new data to be presented at the 2026 American Society of Clinical Oncology annual meeting support the clinical profile of ficerafusp alfa, also referred to by the company as Ficara, in first-line recurrent or metastatic HPV-negative head and neck cancer. On an

MarketBeat

Gene Solutions Showcases AI-Powered Multi-Omics Liquid Biopsy Innovations at TJCC 2026: Advancing Precision Oncology in Taiwan

TAIPEI, May 22, 2026 /PRNewswire/ -- Gene Solutions, an innovative global biotechnology company advancing AI-powered multi-omics solutions for cancer detection and precision oncology, participated in the 30th Taiwan Joint Cancer Conference (TJCC 2026), marking its first major oncology conference presence in Taiwan.

AAP

Read news from The Economist, FT, and more,
with one subscription

CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference

CG Oncology (NASDAQ:CGON) executives used an RBC Capital Markets fireside chat to outline recent clinical data for cretostimogene, the company’s investigational therapy for non-muscle invasive bladder cancer, and to discuss upcoming regulatory, manufacturing and commercial milestones. The discussio

MarketBeat

Auna Q1 Earnings Call Highlights

Auna (NYSE:AUNA) reported stronger first-quarter revenue and cash flow across its regional healthcare platform, while adjusted EBITDA declined as the company absorbed revenue adjustments in Peru and higher payroll costs in Mexico and Colombia. Executive Chairman and President Jesús Zamora said the

MarketBeat

Continuity Biosciences Announces First-in-Human Clinical Trial of Precision Drug Delivery Platform for Pancreatic Cancer

CARY, N.C. and BRADENTON, Fla., May 20, 2026 /PRNewswire/ -- Continuity Biosciences, LLC, a clinical-stage biotechnology company advancing precision drug delivery platforms, today announced the initiation of a Phase I, first-in-human clinical trial evaluating gemcitabine delivered via its iontophoretic oncology platform (IOP) for the treatment of pancreatic cancer. The study,…

AAP

Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data

Aura Biosciences (NASDAQ:AURA) executives outlined the company’s strategy for its lead candidate bel-sar during a session at the H.C. Wainwright Connect Conference, emphasizing ocular oncology as the company’s initial development focus while also discussing ongoing work in non-muscle invasive bladde

MarketBeat

Incyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts Build

Incyte (NASDAQ:INCY) President and CEO Bill Meury said the company’s post-Jakafi growth profile has become “much clearer” over the past year, pointing to continued growth in its commercial business, late-stage pipeline activity and potential launches across oncology and immunology. Speaking at the

MarketBeat

IDEAYA Biosciences Says Melanoma Drug on Track for NDA After Strong Trial Data

IDEAYA Biosciences (NASDAQ:IDYA) said its lead oncology program remains on track for a regulatory submission after reporting positive top-line data in first-line metastatic melanoma, while also highlighting several pipeline programs during a presentation at the Bank of America Global Healthcare Conf

MarketBeat

UK healthcare expansion: Steve Jobs son Reed Jobs plans to invest in cancer startups

Reed Jobs, the son of late Apple co-founder Steve Jobs, is looking to expand investments in British healthcare startups through his oncology-focused venture firm as he pushes efforts to improve cancer treatment and early detection.

The Times of India

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Gilead Sciences Leans on HIV Growth as Deals Build Oncology, Inflammation Pipeline

Gilead Sciences (NASDAQ:GILD) Chief Commercial Officer and Head of Corporate Affairs Johanna Mercier said the company is leaning on its HIV business while continuing to build out oncology and inflammation through recent acquisitions and pipeline development. Speaking at the Bank of America Healthca

MarketBeat

BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM

BioNTech (NASDAQ:BNTX) used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and a restructuring of its manufacturing network. Chairman of the Supervisory Board Helmut Jeggle said the 2

Budget and the Bees

6 Cutting-Edge Cancer Treatments Younger Patients Are Asking Their Oncologists About

Cancer care is changing fast, and younger patients are paying close attention to the newest options available. Many people in their 20s, 30s, and 40s are now researching advanced therapies before they even step into an oncology office. Instead of accepting traditional chemotherapy as the only path forward, they are…

MarketBeat

CG Oncology BLA Filing on Track as Key Bladder Cancer Data Nears

CG Oncology (NASDAQ:CGON) executives said the company remains on track to complete a rolling biologics license application for cretostimogene in BCG-unresponsive high-risk non-muscle invasive bladder cancer by the fourth quarter, while reiterating expectations for top-line data from a separate Phase

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Celcuity Q1 Earnings Call Highlights

Celcuity (NASDAQ:CELC) reported a wider first-quarter loss as the biotechnology company increased spending tied to commercial launch preparations and continued development of gedatolisib, its investigational therapy for hormone receptor-positive, HER2-negative advanced breast cancer. On the company

MarketBeat

PDS Biotechnology Q1 Earnings Call Highlights

PDS Biotechnology (NASDAQ:PDSB) reported a smaller first-quarter loss and highlighted changes to its late-stage head and neck cancer trial that management said could shorten development timelines and reduce costs. On the company’s first quarter 2026 earnings call, Chief Executive Officer Dr. Frank

MarketBeat

Caris Life Sciences Eyes Bigger Oncology Market After IPO as Revenue Jumps 79%

Caris Life Sciences (NASDAQ:CAI) executives said the company is expanding its commercial reach, product pipeline and biopharma partnerships as it looks to build on recent revenue growth following its IPO last June. Speaking at an investor conference, a Caris executive identified by Chief Scientific

MarketBeat

Kura Oncology Q1 Earnings Call Highlights

Kura Oncology (NASDAQ:KURA) reported $5.8 million in first-quarter net product revenue from KOMZIFTI, its first commercial product, and said the launch is showing early signs of physician uptake, broad payer coverage and use in combination regimens, according to management’s earnings call for the fi

MarketBeat

Coherus Oncology Q1 Earnings Call Highlights

Coherus Oncology (NASDAQ:CHRS) said it expects revenue growth for its nasopharyngeal cancer drug LOQTORZI to build through the rest of 2026, while the company prepares for multiple clinical data readouts across its oncology pipeline later this year. On the company’s first-quarter 2026 earnings call

MarketBeat

McKesson Q4 Earnings Call Highlights

McKesson (NYSE:MCK) reported a stronger fiscal fourth quarter and full fiscal 2026 performance, with executives pointing to growth across its oncology, multispecialty, pharmaceutical distribution and prescription technology businesses, while outlining plans for continued earnings growth in fiscal 20

The Guardian - UK

Ann Barrett obituary

Oncologist and authority on paediatric radiotherapy who championed a multidisciplinary, holistic approach

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the University of Glasgow

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.